Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H26N5O8.Gd.3H2O |
| Molecular Weight | 627.7 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O
InChI
InChIKey=WYKPQCVMUQQKCL-UHFFFAOYSA-K
InChI=1S/C16H29N5O8.Gd.3H2O/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;;;;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);;3*1H2/q;+3;;;/p-3
| Molecular Formula | Gd |
| Molecular Weight | 157.25 |
| Charge | 3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H29N5O8 |
| Molecular Weight | 419.4302 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | OMNISCAN Approved UseDiagnostic magnetic resonance imaging (MRI) indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues; facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space. Launch Date1993 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
77.8 min |
0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GADODIAMIDE unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% |
0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GADODIAMIDE unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. | 1998 Sep |
|
| Case-control study of gadodiamide-related nephrogenic systemic fibrosis. | 2007 Nov |
|
| Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. | 2007 Oct 1 |
|
| Nephrogenic systemic fibrosis: possible association with a predisposing infection. | 2008 Apr |
|
| Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. | 2008 Apr |
|
| Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. | 2009 Aug |
|
| NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. | 2010 Nov |
|
| The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. | 2015 Jul |
|
| Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide. | 2016 Jul 11 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:54:51 GMT 2023
by
admin
on
Sat Dec 16 05:54:51 GMT 2023
|
| Record UNII |
0RPE15QPL0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0RPE15QPL0
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY | |||
|
SUB126938
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY | |||
|
122795-43-1
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
DB00225
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY | |||
|
DTXSID9048647
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY | |||
|
31642
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY | |||
|
76964236
Created by
admin on Sat Dec 16 05:54:51 GMT 2023 , Edited by admin on Sat Dec 16 05:54:51 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |